Disfigurement due to scars and dyspigmentation complicating discoid lupus erythematosus (DLE) can be devastating. The cornerstones of therapy for cutaneous lupus erythematosus (CLE) are steroids ...

A new study finds that belimumab (Benlysta®) is an effective therapy option for people with cutaneous lupus erythematosus (CLE), a form of lupus that affects the skin. This study highlights that ...

In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus community underscore the critical need to recognize the unique challenges of ...

Over the past decade, advances in scientists’ understanding of cutaneous lupus erythematosus (CLE) have shed light on the condition’s drivers and set the stage for potential treatments ...

Those with inactive CLE (n = 65) that had positive IFN-alpha activity faced a 4.95 (95% CI, 1.12-21.78) times greater risk for a CLE flare at 6 months vs. those with undetectable IFN-alpha activity.

The retrospective, matched, longitudinal, cohort study included 8,138 patients with strictly CLE and, for comparison, 24,675 patients with systemic lupus erythematosus (SLE), 192,577 with ...

TOPLINE: Atherosclerotic cardiovascular disease (ASCVD) risk is higher with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) than with psoriasis. METHODOLOGY: A ...

There are currently no specific FDA-approved therapies for cutaneous lupus erythematosus (CLE) or discoid lupus erythematosus (DLE) – conditions which mostly affect women and people of color.

HealthDay News — Cutaneous lupus erythematosus (CLE) is associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD), similar to the risk seen in association with ...

The Johns Hopkins Department of Dermatology is conducting a research study led by Dr. Jun Kang to better understand the cellular mechanisms driving disease activity and long-term skin damage in ...

Improvements in Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) scores in patients randomly assigned to receive subcutaneous litifilimab were superior to changes ...